Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China.
Cell Cycle. 2020 Apr;19(8):870-883. doi: 10.1080/15384101.2020.1731052. Epub 2020 Mar 16.
Hepatocellular carcinoma (HCC) is recognized for its high mortality rate worldwide. Based on intensive studies, long non-coding RNA (lncRNA) expression exerts significant effects on tumor suppression. Herein, we investigated the molecular mechanism of lymphoid enhancer-binding factor-1 antisense RNA 1 (LEF1-AS1) in HCC cells. Microarray-based gene expression analysis was adopted to predict and verify the differentially expressed genes in HCC, which predicted cell division cycle-associated 7 (CDCA7) and LEF1-AS1 to be highly expressed in HCC. The expression of LEF1-AS1, CDCA7, CCAAT/enhancer-binding protein beta (CEBPB) and enhancer of zeste homolog 2 (EZH2) was determined by means of reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. LncMap was used to predict the lncRNA-transcription factor-gene interaction in HCC. ChIP, RIP assay and dual luciferase reporter gene assay were employed to verify the relationship between the transcription factor and gene. Silencing of LEF1-AS1 could downregulate CDCA7 expression through CEBPB. Overexpression of LEF1-AS1, EZH2 and CDCA7 promoted proliferation and invasion in HCC cells. LEF1-AS1 promoted CDCA7 expression to further upregulate EZH2. Tumor formation in nude mice was assessed to verify the experimental results. Silencing of LEF1-AS1 inhibited the growth of tumors . Collectively, silencing LEF1-AS1 inhibited the proliferation and invasion of HCC cells by down-regulating EZH2 through the CEBPB-CDCA7 signaling pathway, which provides scientific evidence for the treatment of HCC.: HCC: Hepatocellular carcinoma; lncRNA: long non-coding RNA; LEF1-AS1: lymphoid enhancer-binding factor-1 antisense RNA 1; EZH2: enhancer of zeste homolog 2; CDCA7: cell division cycle-associated 7; GEO: Gene Expression Omnibus; NC: negative control; oe: overexpressed; RT-qPCR: reverse transcription quantitative polymerase chain reaction; PBS: phosphate buffered saline; HRP: horseradish peroxidase; OD: optical density; RIP: Radioimmunoprecipitation; ChIP: Chromatin immunoprecipitation; WT: wild type.
肝细胞癌 (HCC) 是全球高死亡率的癌症。基于深入研究,长链非编码 RNA (lncRNA) 的表达对肿瘤抑制具有显著影响。在此,我们研究了淋巴增强结合因子 1 反义 RNA 1 (LEF1-AS1) 在 HCC 细胞中的分子机制。采用基于微阵列的基因表达分析来预测和验证 HCC 中差异表达的基因,结果预测细胞分裂周期相关蛋白 7 (CDCA7) 和 LEF1-AS1 在 HCC 中高表达。通过逆转录定量聚合酶链反应 (RT-qPCR) 和蛋白质印迹分析确定 LEF1-AS1、CDCA7、CCAAT/增强子结合蛋白β (CEBPB) 和增强子的锌指蛋白 2 (EZH2) 的表达。LncMap 用于预测 HCC 中的 lncRNA-转录因子-基因相互作用。ChIP、RIP 测定和双荧光素酶报告基因测定用于验证转录因子与基因之间的关系。沉默 LEF1-AS1 可通过 CEBPB 下调 CDCA7 的表达。过表达 LEF1-AS1、EZH2 和 CDCA7 可促进 HCC 细胞的增殖和侵袭。LEF1-AS1 促进 CDCA7 的表达,从而进一步上调 EZH2。裸鼠肿瘤形成实验验证实验结果。沉默 LEF1-AS1 抑制肿瘤生长。综上所述,沉默 LEF1-AS1 通过 CEBPB-CDCA7 信号通路下调 EZH2 抑制 HCC 细胞的增殖和侵袭,为 HCC 的治疗提供了科学依据。